Preferences for Sexually Transmitted Infection and Cancer Vaccines in the United States and in China

Overview

Journal Value Health

Publisher Elsevier

Specialties Biomedical Engineering
Pharmacology
Public Health

Date 2022 Sep 2

PMID 36055920

Authors

Abram L Wagner

Yihan Lu

Cara B Janusz

Stephen W Pan

Brian Glover

Zhenke Wu

Lisa A Prosser

Affiliations

Soon will be listed here.

Abstract

Objectives: This study assessed preferences for hypothetical vaccines for children in 2 large vaccine markets according to how the vaccine-preventable disease is transmitted via a discrete choice experiment.

Methods: Surveys in China (N = 1350) and the United States (N = 1413) were conducted from April to May 2021. The discrete choice experiment included attributes of cost, age at vaccination, transmission mode of the vaccine-preventable disease, and whether the vaccine prevents cancer. Preference utilities were modeled in a Bayesian, multinomial logistic regression model, and respondents were grouped by vaccine preference classification through a latent class analysis.

Results: Individuals favored vaccines against diseases with transmission modes other than sexual transmission (vaccine for sexually transmitted infection [STI] vs airborne disease, in the United States, odds ratio 0.71; 95% credible interval 0.64-0.78; in China, odds ratio 0.76; 95% credible interval 0.69-0.84). The latent class analysis revealed 6 classes: vaccine rejecters (19% in the United States and 8% in China), careful deciders (18% and 17%), preferring cancer vaccination (20% and 19%), preferring vaccinating children at older ages (10% and 11%), preferring vaccinating older ages, but indifferent about cancer vaccines (23% and 25%), and preferring vaccinating children at younger ages (10% and 19%). Vaccine rejection was higher with age in the United States versus more vaccine rejection among those at the age of 18 to 24 and ≥ 64 years in China.

Conclusion: The public had strong preferences against giving their child an STI vaccine, and the class preferring a cancer vaccine was less accepting of an STI vaccine. Overall, this study points to the need for more education about how some STI vaccines could also prevent cancers.

Citing Articles

Acceptance of a Future Gonorrhea Vaccine in a Post-Coronavirus Disease 2019 World: Impact of Type of Recommendation and Changing Levels of Trust in Health Institutions and Authorities.

Wagner A, Lacombe-Duncan A, Boulton M Med Clin North Am. 2024; 107(6S):e19-e37.

PMID: 38609279 PMC: 10261718. DOI: 10.1016/j.mcna.2023.06.010.

Public willingness to receive chlamydia, gonorrhea, syphilis, and trichomoniasis vaccines: a scoping review.

Valleroy T, Garon C, Perroud J, Wagner A BMC Health Serv Res. 2023; 23(1):1290.

PMID: 37996885 PMC: 10668406. DOI: 10.1186/s12913-023-10334-9.

References

Wang J, Wagner A, Chen Y, Jaime E, Hu X, Wu S . Would COVID-19 vaccination willingness increase if mobile technologies prohibit unvaccinated individuals from public spaces? A nationwide discrete choice experiment from China. Vaccine. 2021; 40(51):7466-7475. PMC: 8531240. DOI: 10.1016/j.vaccine.2021.10.020. View

Hansen C, Credle M, Shapiro E, Niccolai L . "It All Depends": A Qualitative Study of Parents' Views of Human Papillomavirus Vaccine for their Adolescents at Ages 11-12 years. J Cancer Educ. 2015; 31(1):147-52. PMC: 4508236. DOI: 10.1007/s13187-014-0788-6. View

Hardt K, Bonanni P, King S, Santos J, El-Hodhod M, Zimet G . Vaccine strategies: Optimising outcomes. Vaccine. 2016; 34(52):6691-6699. DOI: 10.1016/j.vaccine.2016.10.078. View

Walling E, Benzoni N, Dornfeld J, Bhandari R, Sisk B, Garbutt J . Interventions to Improve HPV Vaccine Uptake: A Systematic Review. Pediatrics. 2016; 138(1). DOI: 10.1542/peds.2015-3863. View

Zhuang J, Wagner A, Laffoon M, Lu Y, Jiang Q . Procurement of Category 2 Vaccines in China. Vaccines (Basel). 2019; 7(3). PMC: 6789637. DOI: 10.3390/vaccines7030097. View

Robinson C, Bernstein H, Poehling K, Romero J, Szilagyi P . Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(5):130-132. PMC: 7004394. DOI: 10.15585/mmwr.mm6905a3. View

Gidengil C, Lieu T, Payne K, Rusinak D, Messonnier M, Prosser L . Parental and societal values for the risks and benefits of childhood combination vaccines. Vaccine. 2012; 30(23):3445-52. PMC: 8654055. DOI: 10.1016/j.vaccine.2012.03.022. View

Shelton R, Snavely A, De Jesus M, Othus M, Allen J . HPV vaccine decision-making and acceptance: does religion play a role?. J Relig Health. 2011; 52(4):1120-30. PMC: 4616263. DOI: 10.1007/s10943-011-9553-x. View

Savoia E, Piltch-Loeb R, Goldberg B, Miller-Idriss C, Hughes B, Montrond A . Predictors of COVID-19 Vaccine Hesitancy: Socio-Demographics, Co-Morbidity, and Past Experience of Racial Discrimination. Vaccines (Basel). 2021; 9(7). PMC: 8310049. DOI: 10.3390/vaccines9070767. View

10.

Rickert V, Rehm S, Aalsma M, Zimet G . The role of parental attitudes and provider discussions in uptake of adolescent vaccines. Vaccine. 2014; 33(5):642-7. DOI: 10.1016/j.vaccine.2014.12.016. View

11.

Gottlieb S, Johnston C . Future prospects for new vaccines against sexually transmitted infections. Curr Opin Infect Dis. 2016; 30(1):77-86. PMC: 5325242. DOI: 10.1097/QCO.0000000000000343. View

12.

Wang Y, Hu Y, Chen Y, Liang H . Preference and willingness to pay of female college students for human papillomavirus vaccination in Zhejiang Province, China: A discrete choice experiment. Hum Vaccin Immunother. 2021; 17(10):3595-3602. PMC: 8437545. DOI: 10.1080/21645515.2021.1932215. View

13.

Markowitz L, Dunne E, Saraiya M, Chesson H, Curtis C, Gee J . Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014; 63(RR-05):1-30. View

14.

Markowitz L, Dunne E, Saraiya M, Lawson H, Chesson H, Unger E . Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-2):1-24. View

15.

Yang R, Penders B, Horstman K . Addressing Vaccine Hesitancy in China: A Scoping Review of Chinese Scholarship. Vaccines (Basel). 2019; 8(1). PMC: 7157208. DOI: 10.3390/vaccines8010002. View

16.

Grandahl M, Paek S, Grisurapong S, Sherer P, Tyden T, Lundberg P . Parents' knowledge, beliefs, and acceptance of the HPV vaccination in relation to their socio-demographics and religious beliefs: A cross-sectional study in Thailand. PLoS One. 2018; 13(2):e0193054. PMC: 5814087. DOI: 10.1371/journal.pone.0193054. View

17.

Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2095-128. PMC: 10790329. DOI: 10.1016/S0140-6736(12)61728-0. View

18.

Huang Z, Ji M, Ren J, Sun X, Boulton M, Zikmund-Fisher B . Effect of the framing of HPV vaccination on parents' willingness to accept an HPV vaccine. Vaccine. 2022; 40(6):897-903. PMC: 8816874. DOI: 10.1016/j.vaccine.2021.12.051. View

19.

Markowitz L, Tsu V, Deeks S, Cubie H, Wang S, Vicari A . Human papillomavirus vaccine introduction--the first five years. Vaccine. 2012; 30 Suppl 5:F139-48. DOI: 10.1016/j.vaccine.2012.05.039. View

20.

Bryden G, Browne M, Rockloff M, Unsworth C . The privilege paradox: Geographic areas with highest socio-economic advantage have the lowest rates of vaccination. Vaccine. 2019; 37(32):4525-4532. DOI: 10.1016/j.vaccine.2019.06.060. View